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Background: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a recently reported group of disorders
characterized by fibrotic thickening of the pleural and subpleural parenchyma predominantly in the upper lobes.
We report five Japanese cases fulfilling the criteria of IPPFE and address whether it should be considered a separate
clinicopathologic entity. And this study was an attempt to identify features in common between IPPFE and
previously described idiopathic upper lobe fibrosis (IPUF), allowing IPPFE to be considered as a distinct entity in our
Japanese series.
Methods: Five consecutive cases of idiopathic interstitial lung disease confirmed as IPPFE by surgical lung biopsy
were studied.
Results: There were four males and one female, aged 70±2.76 yr. No associated disorder or presumed cause was
found in any case. Lung function tests found a restrictive ventilatory defect (4/5) and/or impairment of DLco (4/5).
Chest X-ray showed marked apical pleural thickening in all cases. Computed tomography of the chest in all cases
mainly showed intense pleural thickening and volume loss associated with evidence of fibrosis, predominantly in
the upper lobes. In all cases in this study, markedly thickened visceral pleura and prominent subpleural fibrosis
characterized by both elastic tissue and dense collagen were clearly shown. All cases were alive at the last follow-up,
17.6±13.59 months after diagnosis; however, all had deteriorated both clinically and radiologically.
Conclusions: IPPFE deserves to be defined as a separate, original clinicopathologic entity owing to its uniformity
and IPPFE has some features in common with previously described idiopathic upper lobe fibrosis (IPUF). Our limited
experience with a cohort of 5 subjects suggests that IPPFE can be rapidly progressive.
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Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a
recently reported rare disorder characterized by fibrotic
thickening of the pleural and subpleural parenchyma
predominantly in the upper lobes [1]; as such IPPFE is
distinct from other types of idiopathic interstitial pneu-
monia [2]. Since 1992 several reports of upper lobe-
predominant pulmonary fibrosis (Idiopathic upper lobe* Correspondence: nakayuta@hama-med.ac.jp
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reproduction in any medium, provided the orfibrosis/IPUF) have been reported in the Japanese litera-
ture [3-9] and some of these cases share features with
IPPFE. Herein we report five Japanese cases of IPPFE,
and describe the clinical, radiologic and evolutionary
profile of IPPFE in a retrospective series in order to de-
termine if IPPFE represents a separate clinicopathologic
entity and to clarify its relationship with IPUF.Methods
The subjects included 5 patients fulfilling criteria IPPFE
diagnosed by surgical lung biopsy [1] (SLB) from May
2009 to Sep 2011 at Hamamatsu University Hospital andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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formed by video-assisted thoracoscopy, and specimens
were obtained from 2 or more lobes in every case. We
used the pathological criteria for the diagnosis of IPPFE
as follows: (1) intense fibrosis of the visceral pleura; (2)
prominent, homogenous, subpleural fibroelastosis; (3)
sparing of the parenchyma distant from the pleura; (4)
mild, patchy lymphoplasmocytic infiltrates; and (5) small
numbers of fibroblastic foci present. All of our reported
cases met all of the criteria. This criteria is based on the
paper by Frankel et al. [1]. Surgical lung specimens
were also reviewed by an expert pulmonary pathologist
(T.V.C.). This study was approved by the Institutional
Review Board of Hamamatsu University School of Medi-
cine. Clinical data were obtained from case medical
records. Laboratory findings and pulmonary function
test results at the time of SLB were also recorded.
Results
Clinical features and biology
Table 1 shows the clinical characteristics and laboratory
data. All patients were more than 60 years of age. There
were no current smokers, and only one patient was an
ex-smoker. Four out of five were classified as under-
weight by body mass index (BMI). The main presenting
symptom was dyspnea. There was no significant family
or occupational history. Case 1 had a history of gingival
cancer, and had chemotherapy. Mild lymphocytosis was
found on BAL in one case. Examination and cultures of
lung tissue for bacteria, mycobacteria, fungi, parasites,
and viruses were negative in all cases. KL-6 was elevated
in two cases and normal in three. Interestingly, the
level of SP-D was higher than the normal range in all
the cases.Table 1 Clinical characteristics and laboratory data
Case.1 Case.2
Age (yr)/sex 70, male 74, female




BAL lym (%) 8.6 0
neu (%) 0.6 0
eos (%) 0 1
KL-6 (U/ml) 410 604
SP-D (ng/ml) 204 131
RF (U/ml) 54 -
ANA - ×40
PaO2 (Torr) 82 94.4
Prognosis Survive 12 months Survive 6 months
Abbreviations: BMI, body mass index, BAL, broncho-alveolar lavage, KL-6, Sialylated
ANA, antinuclear antibody.Pulmonary function test
All cases underwent a spirometry test and measurement
of total lung capacity (TLC). A restrictive ventilatory de-
fect defined by %FVC < 80% was found in 4 cases. In
addition, four cases had impairment of DLco (Table 2).
Radiological features
Chest radiographs in all cases showed marked apical
pleural thickening and superior hilar retraction
(Figure 1). Right lung is predominantly affected in case
2, 3, and 5, left lung in case 4. High-resolution CT
(HRCT) showed intense pleural thickening associated
with evidence of fibrosis. In Case 1 and 2, upper lobe
volume loss, architectural distortion and traction bron-
chiectasis were also prominent.
Pathological features
In all cases in this study, the histopathological findings fit-
ted those previously described for IPPFE. Markedly thick-
ened visceral pleura and prominent subpleural fibrosis
characterized by both elastic tissue and dense collagen
were clearly shown (Figures 2a, b and 3a, b). The border
between the fibroelastosis and the underlying normal lung
parenchyma was abrupt, and the parenchyma distant from
the pleura was spared (Figure 2a). Fibroblastic foci were
rarely noted at the leading edge of the fibrosis. Inflamma-
tion was variable and primarily consisted of small aggre-
gates of lymphocytes. Asbestos bodies were absent.
Treatment and clinical outcome
All cases initially had no treatment. The mean duration
of follow-up after the pathologic diagnosis was
12.1 months (range 4.4 - 22). The total duration of
follow-up from the onset of the symptoms to the lastCase.3 Case.4 Case.5













Survive 44 months Survive 10 months Survive 16 months
carbohydrate antigen KL-6, Sp-D, Surfactant Protein D, RF, rheumatoid factor,
Table 2 Pulmonary function test data
Case.1 Case.2 Case.3 Case.4 Case.5
TLC (L), %predicted (%) 4.09 (79.4) 2.90 (79.0) 5.97 (107.4) 3.69 (72.1) 2.9 (56.9)
FVC (L), %predicted (%) 2.50 (74.1) 1.41 (74.1) 3.24 (93.6) 2.14 (63.7) 2.12 (64.0)
FEV1 (L), %predicted (%) 2.06 (77.5) 1.33 (87.5) 3.20 (101.6) 2.11 (79.0) 1.67 (64.3)
FEV1.0/FVC 90.4 95 96.7 96.3 96.5
FRC (L), %predicted (%) 3.0 (75.2) 2.1 (101) 3.87 (85.6) 2.61 (67.3) 2.14 (51.8)
RV (L), %predicted (%) 1.97 (121.6) 1.42 (87.1) 2.82 (154.1) 1.55 (100) 1.38 (84.1)
RV/TLC (%), %predicted (%) 48.17 (120.2) 48.97 (145.1) 47.2 (120.7) 42.0 (107.2) 47.59 (111.2)
DLco (mL/min/mmHg), %predicted (%) 9.41 (74.2) 9.94 (76.8) 10.55 (71.3) 12.51 (96.1) 6.12 (55.1)
DLco/VA (mL/min/mmHg), %predicted (%) 3.04 (69.1) 4.42 (103.3) 2.10 (47.1) 4.42 (98.4) 2.78 (64.5)
Abbreviations: TLC, Total lung capacity, FVC, Forced vital capacity, FEV, Forced expiratory volume, FRC, Functional residual capacity, RV Residual volume, DLco,
Diffusing capacity for carbon monoxide, DLco/VA, Diffusing capacity divided by the alveolar volume.
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were alive at the last follow-up (Table 2), but all had dis-
ease progression according to clinical and lung function
tests, especially in terms of %FVC (Figure 4).
Discussion
It is clear that IPPFE is not a new pulmonary disease. As
Reddy et al [10] reported, it has previously received
other names, such as idiopathic upper lobe fibrosisCase.1 Case.2 Case.
Figure 1 Chest X-ray and Chest CT. Chest radiographs in all cases showe
upper lobe volume loss, architectural distortion, traction bronchiectasis, and(IPUF), and has more frequently been described in the
Japanese literature [3-5,9] and may be more common in
the Japanese. IPPFE has been defined as a distinct entity
in the English literature by Frankel et al.; a unique clin-
ical presentation and precise characteristic pathologic
criteria are described [1]. Our study was an attempt to
identify features in common between these two entities,
allowing IPPFE to be considered distinct as it applies to
our Japanese series.3 Case.5Case.4
d marked apical pleural thickening. High-resolution CT (HRCT) showed
reticular abnormalities. There was no honeycombing.
a b
Figure 2 Histopathological Findings (hematoxylin-eosin). Surgical lung biopsy specimen at low power (a:case 1, b:case 5) and high power (a,
inset) showed markedly thickened visceral pleura and prominent subpleural fibrosis characterized by abnormal increase of elastic tissue and
dense collagen. Abrupt transition to normal parenchyma was also seen. Parenchyma distant from the pleura was spared.
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function tests were characteristic of restrictive interstitial
lung disease. Radiological features were also characteris-
tic, including intense pleural thickening associated with
evidence of fibrosis, most striking pattern in the upper
lobes with volume loss and architectural distortion. The
upper lobes were always more severely involved, with
involvement of the lower lobes being absent or less
marked. Piciucchi and colleagues reported that one case
had honeycombing on HRCT findings in their cases
[11]. In our series, no patients had honeycombing. In all
the reports describing PPFE, eight out of total 25 cases
(32%) had a history of malignancy. Among those cases,
four cases had treatment with BMT [12] and those cases
presented with histological evidence of obliterative
bronchiolitis, which was not a feature in those with
idiopathic presentation of PPFE, suggesting that bonea
Figure 3 Histopathological Findings (Elastic Van Gieson). Surgical lung
an abundance of short, amorphous elastic fibers (Case 1).marrow transplantation is a potential etiology at least in
a subgroup of cases with pleuroparenchymal fibroelasto-
sis. In our series, Case 1 had a history of gingival cancer
treated with surgery followed by adjuvant chemotherapy.
However, no cases had BMT, and other cases never had
malignancy.
In terms of therapy and prognosis, previous cases of
IPPFE showed a 40% mortality rate. In addition, many
cases gradually deteriorated. In our series, consistent with
previous reports, although no death occurred, all the cases
clinically and functionally deteriorated even in a relatively
short follow-up period. There are no therapeutic options
available for IPPFE except for supportive care and ultim-
ately lung transplantation. Regarding the mechanism of
elastosis, it has not been determined whether fibroelasto-
sis occurred by overproduction of elastin or impairment
of degradation. Pirfenidone is an antifibrotic drug,b






















Figure 4 Clinical Course of the cases. Case 1 radiologically deteriorated a year after diagnosis (a, b). Other cases present similar behavior.
(c) Decrease in FVC was confirmed in all cases during the follow up. The median follow up was 12.1 (range 4.37-22.2) months.
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[13-15], which inhibits fibrotic factors, most notably
TGFβ. As a consequence, downstream synthesis of extra-
cellular matrix proteins, such as fibronectin, elastin and
collagen, is reduced [16,17]. Hence, it may potentially be
beneficial for cases of IPPFE.
There are several case reports of idiopathic, upper lobe-
predominant fibrosis in the Japanese language literature
[3-6,9]. Among those reports, it has been described that
the thinness of the body was a characteristic of the disease.Consistent with these reports, our cases showed low BMI.
However, there are no data on BMI or body weight of
patients with IPPFE in reports from outside of Japan.
Radiologically upper lobe predominance is associated with
both IPUF and IPPFE. As both IPUF and IPPFE are rela-
tively rare and only recently described, there are no guide-
lines or criteria as to how extensive the opacities in the
middle and lower lobes can be. In terms of other aspects
of the disease, such as possible occurrence of pneumo-
thorax, infection and slow progression of the disease,
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disease. Although IPUF patients with surgical lung biopsy
or autopsy were reported in some Japanese literature,
there are no pathological criterias as IPUF. But in all those
cases, intraalveolar fibrosis and subpleural elastosis were
noted. Those findings are same to the pathological find-
ings with IPPFE. Interestingly, the specimens from some
patients shows UIP like pattern in the lower lobe. Amitani
et al. [9] strictly defined the lesion is in the upper lobe, but
the report from Shiota et al. [6] include the patients with
UIP like lesion. Reddy [10] also mentioned patients with
PPFE had the fibrosis in the lower lobe. Further studies
are needed what is the possible lesion in mid-lower lobe.
Finally, pulmonary surfactant protein D (SP-D) was ele-
vated in all cases in our series. It is expressed in alveolar
type II and bronchiolar epithelial cells and is secreted into
alveoli and conducting airways [18,19]. Our data suggest
that those epithelial cells may play a role in the fibrotic
process of the diseases.
There are some limitations to the present study. First,
there were selection and recall biases because this was a
retrospective study. Since the current authors’ institu-
tions are regional referral centers for diffuse lung dis-
ease, the proportion and severity of the disease reported
here may differ substantially from those found in the
community. Second, the sample size was too small to
determine the precise prevalence and clinical character-
istics of IPPFE. Prospective studies incorporating larger
series are necessary to verify these results.
Conclusions
This study shows that the clinical, radiological and
pathological presentation of IPPFE is remarkably uni-
form in cases with apparently idiopathic lung disease.
We thus consider that idiopathic PPFE deserves to be
defined as a distinct clinicopathological syndrome largely
overlapping with previously described IPUF. It should be
distinguished from other types of interstitial lung dis-
ease, especially because it is highly progressive.
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